Market revenue in 2022 | USD 141.9 million |
Market revenue in 2030 | USD 245.0 million |
Growth rate | 7.1% (CAGR from 2022 to 2030) |
Largest segment | Reagents & consumables |
Fastest growing segment | Reagents & Consumables |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Analyzers, Reagents & Consumables |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.26% in 2022. Horizon Databook has segmented the France thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing prevalence of blood clotting disorders in the population, growing healthcare spending, and the availability of diagnostic tests & treatments are expected to boost the country’s market. The increasing geriatric population and rising chronic diseases are contributing to the further growth of the market.
Thrombosis and hemostasis biomarkers serve as diagnostic & monitoring tools for different blood clotting conditions, such as DVT & PE. These biomarkers aid in identifying patients who are at high risk of developing blood clots and track the efficacy of the treatments.
For instance, according to the BMC Journal, the estimated incidence of VTE in France is 184.0 per 100,000 population, and the incidence of PE is 64.2 per 100,000 population. Some of the key players in the market are Roche Diagnostics, Siemens Healthcare, and Abbott Laboratories.
Horizon Databook provides a detailed overview of country-level data and insights on the France thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into France thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account